We have located links that may give you full text access.
Case Reports
Journal Article
Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease.
Journal of Dermatological Treatment 2005 Februrary
BACKGROUND: Hidradenitis suppurativa is a chronic, inflammatory, scarring disease characterized by recurrent flares. Recently, a group of 'autoinflammatory disorders' has been described. These disorders are characterized by recurrent inflammatory episodes not mediated by autoantibodies or antigen-specific T-cells. Some of these autoinflammatory disorders have been successfully treated with anti-tumor necrosis factor antibodies.
OBSERVATIONS: We describe a patient with hidradenitis suppurativa and a history of inactive Crohn's disease who was treated with infliximab, with subsequent improvement in her skin disease.
CONCLUSIONS: This case suggests that infliximab may be effective in the treatment of hidradenitis suppurativa in association with Crohn's disease. We also suggest that hidradenitis suppurativa may be closely linked with this new group of autoinflammatory disorders.
OBSERVATIONS: We describe a patient with hidradenitis suppurativa and a history of inactive Crohn's disease who was treated with infliximab, with subsequent improvement in her skin disease.
CONCLUSIONS: This case suggests that infliximab may be effective in the treatment of hidradenitis suppurativa in association with Crohn's disease. We also suggest that hidradenitis suppurativa may be closely linked with this new group of autoinflammatory disorders.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app